Hepatic Cell News Volume 7.39 | Oct 20 2023

    0
    8








    2023-10-20 | HCN 7.39


    Hepatic Cell News by STEMCELL Technologies
    Vol. 7.39 – 20 October, 2023
    TOP STORY

    Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase III trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease (NAFLD) and presumed nonalcoholic steatohepatitis.
    [Nature Medicine]

    Full Article
    Are Your Pluripotent Stem Cells What You Think They Are? Explore Now.
    PUBLICATIONSRanked by the impact factor of the journal

    Unaltered Hepatic Wound Healing Response in Male Rats with Ancestral Liver Injury

    The authors comprehensively investigated the transgenerational effects by repeating the original carbon tetrachloride multigenerational study with increased power, pedigree tracing, F2 dose-response, and suitable randomization schemes.
    [Nature Communications]

    Full Article

    URI Alleviates Tyrosine Kinase Inhibitors-Induced Ferroptosis by Reprogramming Lipid Metabolism in p53 Wild-Type Liver Cancers

    Researchers uncovered that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endowed HCC with resistance to tyrosine kinase inhibitor-induced ferroptosis.
    [Nature Communications]

    Full Article

    Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

    Scientists examined the spectrum of acquired resistance mechanisms detected in circulating tumor DNA or tumor tissue upon disease progression following FGFR inhibitor therapy in 82 FGFR-altered cholangiocarcinoma patients from 12 published reports.
    [Clinical Cancer Research]

    Abstract

    USP39 Promotes Hepatocellular Carcinogenesis through Regulating Alternative Splicing in Cooperation with SRSF6/HNRNPC

    Investigators observed that hepatocyte-specific overexpression of ubiquitin-specific protease 39 (USP39) promoted hepatocarcinogenesis and potently regulated splice site selection in transgenic mice. In human liver cancer cells, USP39 promoted tumor proliferation in a spliceosome-dependent manner.
    [Cell Death & Disease]

    Full ArticleGraphical Abstract

    Sorcin Regulate Pyroptosis by Interacting with NLRP3 Inflammasomes to Facilitate the Progression of Hepatocellular Carcinoma

    The authors manifested that Sorcin was considerably upregulated, whereas pyroptosis-associated proteins were significantly decreased in HCC tissues and cells.
    [Cell Death & Disease]

    Full Article

    Hesperetin Derivative 2a Inhibits Lipopolysaccharide-Induced Acute Liver Injury in Mice via Downregulation of circDcbld2

    Scientists investigated the mechanisms of occurrence and development of acute liver injury (ALI) in lipopolysaccharide-induced ALI mice.
    [Acta Pharmacologica Sinica]

    Abstract

    lncRNA SNHG9 Enhances Liver Cancer Stem Cell Self-Renewal and Tumorigenicity by Negatively Regulating PTEN Expression via Recruiting EZH2

    Researchers investigated the function of long noncoding RNA small nucleolar RNA host gene 9 (SNHG9) in liver cancer stem cell self-renewal and tumorigenesis.
    [Cell And Tissue Research]

    Abstract

    Gallic Acid Promotes Ferroptosis in Hepatocellular Carcinoma via Inactivating Wnt/β-Catenin Signaling Pathway

    Investigators identified a critical role of gallic acid (GA) in inducing ferroptosis in HepG2 cells. They confirmed that GA is a novel ferroptosis inducer of HCC.
    [Naunyn-Schmiedebergs Archives Of Pharmacology]

    Abstract
    Register for a recorded organoid panel discussion moderated by Dr. James Wells
    REVIEWS

    Role of Exosomes in the Development, Diagnosis, Prognosis, and Treatment of Hepatocellular Carcinoma

    Scientists review the role of exosomes involved in the proliferation, migration, and metastasis of HCC and describe their application in HCC diagnosis and treatment.
    [Molecular Medicine]

    Full Article

    Pharmacokinetic Considerations for Angiogenesis Inhibitors Used to Treat Hepatocellular Carcinoma: An Overview

    The authors summarize the pharmacokinetic characteristics of the antigiogenic drugs currently approved for the treatment of HCC, from oral tyrosine kinase inhibitors to monoclonal antibodies.
    [Expert Opinion on Drug Metabolism & Toxicology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

    Metabolon, Inc., announced the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.
    [Metabolon Inc.]

    Press Release

    Argentina Election: Front Runner Vows to Slash Science Funding

    Scientists in Argentina are on edge as the country’s presidential election approaches. If elected president, economist Javier Milei has pledged to eliminate government spending on research and shut down the environment and health ministries.
    [Nature]

    Press Release
    FEATURED EVENT

    AACR-KCA Joint Conference on Precision Medicine in Cancer

    November 15 – 17, 2023
    Seoul, Korea

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Scientist – Integrative Modelling

    CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom

    Postdoctoral Fellow – Bioinformatics

    The University of Hong Kong – Hong Kong, Hong Kong

    Director – Center of Emphasis in Diabetes and Metabolism

    Texas Tech University Health Sciences Center El Paso – El Paso, Texas, United States

    Research Assistant – Hepatitis Research

    National University of Singapore – Singapore, Singapore

    Research Assistant – Department of Medicine

    National University of Singapore – Singapore, Singapore

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hepatic Cell News Twitter